Indacaterol/Glycopyrronium
Treatment for Chronic Bronchitis
Typical Dosage: 27.5 mcg/15.6 mcg or 110 mcg/50 mcg once daily
Effectiveness
78%
Safety Score
60%
Clinical Trials
100
Participants
25K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
27.5 mcg/15.6 mcg or 110 mcg/50 mcg once daily
Time to Effect
Within 5 minutes
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
9(Treat 9 patients to see 1 additional successful outcome)
Confidence Score
92%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$5,500
Monitoring:$600
Side Effect Mgmt:$100
Total Annual:$6,200
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$60,000/QALY
QALYs Gained
0.1
Outcome-Based Costs
Cost per Responder
$8,267
Cost per Remission
$124,000
Comparison vs Tiotropium
Cost Difference
+$1,000/year
More expensive
QALY Difference
+0.02 QALYs
Better outcomes
Dominance
No dominance
Indacaterol/Glycopyrronium Outcomes
for Chronic Bronchitis
Efficacy Outcomes
Overall Effectiveness
+78%
Response Rate
+75%
Remission Rate
+5%
Common Side Effects
Nasopharyngitis
+6.5%
Cough
+5.5%
Headache
+3.5%
Urinary tract infection
+2.5%
Dry mouth
+1.5%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov